Try our Advanced Search for more refined results

In re Avalanche Biotechnologies Securities Litigation

  1. November 04, 2016

    Avalanche Biotechnologies Escapes IPO Suit Over Eye Drug

    Avalanche Biotechnologies Inc. on Thursday won dismissal in California federal court of an investor suit accusing it of misleading investors about the effectiveness of its gene therapy for vision loss before its initial public offering, but the judge said the investors can try again with an amended complaint.

  2. August 31, 2016

    Avalanche Aims To Ditch IPO Suit Over Eye Drug

    Avalanche Biotechnologies Inc. on Wednesday asked a California federal judge to toss a proposed investor class action alleging it knew a gene therapy for vision loss didn't work before its public offering, saying the plaintiffs had failed to prove that the company learned halfway through clinical trials that the treatment wasn't effective.

  3. September 03, 2015

    Avalanche, Investors Ask To Consolidate Stock Drop Suits

    Avalanche Biotechnologies Inc. and a putative class of investors suing the company over a stock drop they claim were due to misrepresentations about a vision treatment's clinical trial design asked a California federal judge Wednesday to consolidate three cases into a single proceeding.

  4. July 10, 2015

    Avalanche Hit With Stock Drop Suit Over Eye Drug Study

    Avalanche Biotechnologies Inc. was sued in California federal court Thursday for allegedly misleading shareholders about a clinical trial's design, to inflate the share price before and after the vision treatment developer's initial public offering, and for causing a major stock drop.